Sanofi
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SNY research report →
About the company
Sanofi operates as a leading global pharmaceutical enterprise, dedicated to the research, development, production, and distribution of a wide array of therapeutic solutions across the United States, Europe, and numerous international markets. The company strategically organizes its operations into three core divisions: Pharmaceuticals, Vaccines, and Consumer Healthcare. Within its Pharmaceutical segment, Sanofi delivers specialized therapies, including innovative human monoclonal antibodies, addressing complex conditions like multiple sclerosis, various neurological disorders, immunology and inflammatory diseases, oncology, rare diseases, and rare blood disorders.
- CEO
- Belén Garijo López
- IPO
- 2002
- Employees
- 82,878
- HQ
- Paris, IF, FR
Price Chart
Get TickerSpark's AI analysis on SNY
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
- Market Cap
- $107.37B
- P/E
- 12.48
- P/S
- 1.96
- P/B
- 1.28
- EV/EBITDA
- 12.70
- Div Yield
- 5.33%
- Gross Margin
- 71.92%
- Op Margin
- 19.84%
- Net Margin
- 15.95%
- ROE
- 10.51%
- ROIC
- 7.50%
- Revenue
- $46.72B · 5.49%
- Net Income
- $7.81B · 40.52%
- EPS
- $3.20 · 45.79%
- Op Income
- $9.60B
- FCF YoY
- 72.34%
- 52W High
- $52.68
- 52W Low
- $40.89
- 50D MA
- $43.35
- 200D MA
- $46.77
- Beta
- 0.28
- Avg Volume
- 3.21M
Our SNY coverage
Recent articles, reports, and earnings notes.
Sanofi (SNY): Dupixent Drives a Buy Case
Sanofi is becoming a more focused biopharma compounder, led by Dupixent growth, vaccine strength, and expanding launch sales. The stock looks inexpensive versus its cash generation and earnings power.
Talawar Tx SPAC Merger: A Preclinical Biotech Cash-Runway Test
Talawar Tx is a preclinical biotechnology company focused on bispecific antibodies for immunology and inflammatory diseases, and it is going public through a merger with JATT II Acquisition Corp. The deal is expected to close in the second half of 2026, with the setup favoring investors who want exposure to a large-market biotech story but should watch redemption risk and dilution closely.
Vertex just got a bigger CASGEVY market, and Wall Street may still be underestimating it
Vertex’s CASGEVY expansion to patients as young as 2 looks like a real commercial runway extension, not a cosmetic label update. With elite margins, strong growth, and a TickerSpark Score of 89, the stock still looks built for more than a one-day pop.
Want a deeper read on SNY?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Similar companies
Peers in the same neighborhood.